辅助化疗对激素受体阳性A型乳腺癌女性患者有用吗？ - Suppr

Suppr

超能文献

Is adjuvant chemotherapy useful for women with luminal a breast cancer?

作者信息

Coates Alan S, Colleoni Marco, Goldhirsch Aron

机构信息

International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia.

出版信息

J Clin Oncol. 2012 Apr 20;30(12):1260-3. doi: 10.1200/JCO.2011.37.7879. Epub 2012 Feb 21.

DOI:10.1200/JCO.2011.37.7879

PMID:22355052

Abstract

摘要

相似文献

Is adjuvant chemotherapy useful for women with luminal a breast cancer?辅助化疗对激素受体阳性A型乳腺癌女性患者有用吗？

J Clin Oncol. 2012 Apr 20;30(12):1260-3. doi: 10.1200/JCO.2011.37.7879. Epub 2012 Feb 21.

Targeting adjuvant chemotherapy: a good idea that needs to be proven!靶向辅助化疗：一个有待证实的好想法！

J Clin Oncol. 2012 Apr 20;30(12):1264-7. doi: 10.1200/JCO.2011.38.4529. Epub 2012 Feb 21.

Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.保乳治疗早期乳腺癌中乳腺癌亚型对乳腺癌特异性生存、远处转移和局部复发率的预后价值：一项回顾性临床研究。

Eur J Surg Oncol. 2011 Oct;37(10):876-82. doi: 10.1016/j.ejso.2011.07.001. Epub 2011 Aug 6.

[Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].[早期浸润性乳腺癌的保乳治疗：局部复发挽救治疗后生存的预后因素]

Magy Onkol. 2007;51(2):127-31. Epub 2007 Jul 29.

The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.芳香化酶抑制剂在激素受体阳性绝经后乳腺癌女性中的应用。

J Clin Oncol. 2005 Sep 20;23(27):6807-9. doi: 10.1200/JCO.2005.02.3952.

[Effectiveness of adjuvant systemic therapy in organ preserving treatment of pT1-2N0M0 breast cancer].[辅助全身治疗在pT1-2N0M0乳腺癌保乳治疗中的有效性]

Vopr Onkol. 1999;45(5):516-9.

To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?换用还是不换用：他莫昔芬与雷洛昔芬（STAR）试验的研究是否应改变我们的决策？

Taiwan J Obstet Gynecol. 2008 Sep;47(3):372-4. doi: 10.1016/S1028-4559(08)60149-7.

Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.早期对乳腺癌新辅助化疗的反应既可以预测保乳手术的成功，也可以降低同侧乳房肿瘤复发的风险。

Breast J. 2010 Jan-Feb;16(1):9-13. doi: 10.1111/j.1524-4741.2009.00864.x. Epub 2009 Nov 19.

Limited surgery and tamoxifen in the treatment of elderly breast cancer patients.有限手术与他莫昔芬治疗老年乳腺癌患者

World J Surg. 2003 Feb;27(2):125-9. doi: 10.1007/s00268-002-6530-2.

Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.早期乳腺癌治疗的国际治疗指南及预后检测评估

Cancer Treat Rev. 2008 Dec;34(8):701-9. doi: 10.1016/j.ctrv.2008.04.002. Epub 2008 Oct 14.

引用本文的文献

Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.Prosigna检测对早期激素受体阳性/人表皮生长因子受体2阴性乳腺癌患者新辅助治疗决策的影响：一项单中心前瞻性观察研究

ESMO Open. 2025 Jul 25;10(8):105521. doi: 10.1016/j.esmoop.2025.105521.

The Effect of Blood Selenium Level on the pCR Rate in Breast Cancer Patient Receiving Neoadjuvant Chemotherapy.血硒水平对接受新辅助化疗的乳腺癌患者病理完全缓解率的影响

Cancers (Basel). 2025 Feb 28;17(5):839. doi: 10.3390/cancers17050839.

Invasive papillary carcinoma of the breast: A case report.乳腺浸润性乳头状癌：一例报告。

Oncol Lett. 2024 May 2;28(1):300. doi: 10.3892/ol.2024.14433. eCollection 2024 Jul.

Autocrine phosphatase PDP2 inhibits ferroptosis by dephosphorylating ACSL4 in the Luminal A Breast Cancer.自分泌磷酸酶PDP2通过使腔面A型乳腺癌中的ACSL4去磷酸化来抑制铁死亡。

PLoS One. 2024 Mar 11;19(3):e0299571. doi: 10.1371/journal.pone.0299571. eCollection 2024.

Dendritic Cell Subpopulations Are Associated with Prognostic Characteristics of Breast Cancer after Neoadjuvant Chemotherapy-An Observational Study.树突状细胞亚群与新辅助化疗后乳腺癌的预后特征相关：一项观察性研究。

Int J Mol Sci. 2023 Oct 31;24(21):15817. doi: 10.3390/ijms242115817.

Evaluation of the efficacy of chemotherapy for tubular carcinoma of the breast: A Surveillance, Epidemiology, and End Results cohort study.评价乳腺癌管状癌化疗的疗效：监测、流行病学和最终结果队列研究。

Cancer Med. 2023 May;12(9):10326-10339. doi: 10.1002/cam4.5763. Epub 2023 Mar 6.

Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.术前接受新辅助化疗的激素受体阳性且人表皮生长因子受体2阴性乳腺癌患者的预后：一项回顾性分析。

Cancers (Basel). 2023 Feb 10;15(4):1157. doi: 10.3390/cancers15041157.

Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.中国多中心回顾性研究：激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌新辅助化疗后乳腺病理完全缓解和无病生存的真实世界数据。

World J Surg Oncol. 2022 Sep 29;20(1):326. doi: 10.1186/s12957-022-02787-9.

Luminal A Breast Cancer: How Feasible is Omitting Axillary Dissection Without Neoadjuvant Therapy.管腔 A 型乳腺癌：新辅助治疗情况下省略腋窝清扫术的可行性如何。

Breast J. 2022 Jul 30;2022:8284814. doi: 10.1155/2022/8284814. eCollection 2022.

Effect of radiotherapy sequence on long-term outcome in patients with node-positive breast cancer: a retrospective study.放疗顺序对淋巴结阳性乳腺癌患者长期预后的影响：一项回顾性研究。

Sci Rep. 2022 Jun 24;12(1):10729. doi: 10.1038/s41598-022-14873-9.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验